Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.626
AS - Asia 4.447
EU - Europa 3.522
SA - Sud America 736
AF - Africa 66
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.407
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.455
SG - Singapore 1.734
HK - Hong Kong 1.052
CN - Cina 1.002
RU - Federazione Russa 812
IE - Irlanda 609
BR - Brasile 599
IT - Italia 560
DE - Germania 472
SE - Svezia 460
VN - Vietnam 231
GB - Regno Unito 161
CA - Canada 126
UA - Ucraina 112
IN - India 98
AT - Austria 72
FI - Finlandia 69
AR - Argentina 60
ID - Indonesia 58
TR - Turchia 49
JP - Giappone 43
FR - Francia 42
BD - Bangladesh 41
DK - Danimarca 38
MX - Messico 31
KR - Corea 25
IQ - Iraq 23
ZA - Sudafrica 23
NL - Olanda 22
PL - Polonia 22
EC - Ecuador 20
BE - Belgio 19
ES - Italia 17
SA - Arabia Saudita 16
CO - Colombia 13
UZ - Uzbekistan 10
VE - Venezuela 10
PE - Perù 9
PY - Paraguay 9
UY - Uruguay 9
IR - Iran 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
KE - Kenya 7
AU - Australia 6
CL - Cile 6
DZ - Algeria 5
EG - Egitto 5
JM - Giamaica 5
JO - Giordania 5
MU - Mauritius 5
NP - Nepal 5
RO - Romania 5
AM - Armenia 4
BG - Bulgaria 4
MA - Marocco 4
TN - Tunisia 4
TW - Taiwan 4
AL - Albania 3
DO - Repubblica Dominicana 3
IL - Israele 3
KZ - Kazakistan 3
LT - Lituania 3
NG - Nigeria 3
PS - Palestinian Territory 3
SN - Senegal 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
EU - Europa 2
GR - Grecia 2
IS - Islanda 2
LB - Libano 2
MT - Malta 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
CH - Svizzera 1
CY - Cipro 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
ML - Mali 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
Totale 17.399
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.331
Hong Kong 1.037
Singapore 1.025
Fairfield 850
Ashburn 798
Dublin 601
Woodbridge 481
Wilmington 435
Seattle 389
Chandler 372
Houston 323
Cambridge 320
Frankfurt am Main 281
New York 274
Princeton 248
Beijing 212
Jacksonville 166
Santa Clara 145
Shanghai 131
Altamura 122
Los Angeles 119
Lawrence 118
Milan 110
The Dalles 103
Dallas 92
Chicago 87
Moscow 77
San Diego 73
Dearborn 63
Ho Chi Minh City 62
Toronto 52
São Paulo 51
Vienna 49
Jakarta 48
Buffalo 45
Andover 44
Hanoi 43
Helsinki 42
London 39
Guangzhou 38
Boardman 34
Hefei 32
Nanjing 32
Salt Lake City 30
Munich 29
Hangzhou 28
Nuremberg 28
Rio de Janeiro 27
Turin 26
Ottawa 25
Tokyo 25
Pune 24
Washington 24
Council Bluffs 23
Falls Church 23
Dong Ket 22
Rome 21
Brussels 18
Norwalk 18
Seoul 16
Jinan 15
Phoenix 15
Tianjin 15
Columbus 14
Tampa 14
Brasília 13
Hebei 13
Redmond 13
San Francisco 13
Zhengzhou 13
Atlanta 12
Boston 12
Brooklyn 12
Elk Grove Village 12
Lachine 12
Torre Del Greco 12
Warsaw 12
Changsha 11
Chennai 11
Porto Alegre 11
San Jose 11
Belo Horizonte 10
Haiphong 10
Mumbai 10
Tappahannock 10
Da Nang 9
Guayaquil 9
Johannesburg 9
Amsterdam 8
Baghdad 8
Denver 8
Dhaka 8
Edmonton 8
Montreal 8
Nanchang 8
Perugia 8
Poplar 8
Stockholm 8
Tashkent 8
Biên Hòa 7
Totale 11.829
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 388
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 347
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 328
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 316
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 309
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 304
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 296
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 288
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 276
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 271
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 261
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 258
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 245
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 244
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 241
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 225
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 220
When progressive dysphagia could be related to an “old friend” – a case report 208
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 207
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 201
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 198
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 194
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 192
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 181
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 181
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 175
Novel cytotoxic chemotherapies in small cell lung carcinoma 173
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 172
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 168
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 167
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 160
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 159
Focus on nivolumab in NSCLC 157
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 155
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 154
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 154
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 154
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 151
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 151
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 148
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 146
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 143
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 142
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer 140
Drugs ten years later: epirubicin 138
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 138
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 136
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 135
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 133
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 132
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 130
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 130
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 128
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 128
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 125
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 124
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 121
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 121
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 121
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 120
Pilot study with adriamycin and ifosfamide in small cell lung cancer 119
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 118
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 117
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 117
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 116
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 115
A new race against lung cancer 114
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 114
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 114
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 113
Oxaliplatin doublets in non-small cell lung cancer: A literature review 112
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 112
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 110
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 109
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 109
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 108
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 108
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 108
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 108
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 107
Targeted therapies and immunotherapy in non-small-cell lung cancer 106
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 106
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 106
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 106
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 103
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 103
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 103
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 102
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 100
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 99
Isolated cardiac metastasis from squamous cell esophageal cancer 98
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 98
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 98
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 97
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 96
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 96
Esophageal carcinoma: radiochemotherapy 95
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 95
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 94
Corrigendum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (British Journal of Cancer (2016) 115 (789-796) DOI: 10.1038/bjc.2016.271) 94
Totale 15.651
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.041
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.041
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.610 0 0 0 0 0 185 293 324 219 220 179 190
2021/20221.233 107 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.867 32 36 59 59 272 498 377 101 205 14 17 197
2024/20253.752 219 500 198 171 301 132 213 80 463 555 277 643
2025/20263.731 783 521 464 642 908 413 0 0 0 0 0 0
Totale 18.015